Clinical trials: CMV
Cytomegalovirus (CMV)
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with…
- Trial name
- NCT01611974
- Testing
- Maribavir
- Where
- 32 sites in United States
- Volunteers
- 120 people
- Sponsor
- Shire
CMV, EBV
Cytotoxic T Cells to Prevent Virus Infections
In this study, investigators are trying to see if infusion of "m-CTLs" will prevent or treat cytomegalovirus (CMV), Epstein Barr Virus (EBV) and adenovirus (AdV) reactivation or infection after cord blood transplant.
- Conditions
- CMV, EBV, Adenovirus Infections
- Trial name
- NCT01923766
- Testing
- Cytotoxic T lymphocytes (CTLs).
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Children's National Research Institute
CMV Infection
Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation
Cytomegalovirus (CMV) infections remain an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HSCT) recipients, especially in patients received haploidentical transplantation.
- Trial name
- NCT02985775
- Testing
- Donor-derived CMVpp65-specific T cells
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Peking University People's Hospital
Congenital Cytomegalovirus (CMV)
Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance
Congenital cytomegalovirus (CMV) infection is the leading cause of non-genetic neurosensory deafness and affects 0.5 to 1% of births.
- Trial name
- GANCIMVEAR (NCT02606266)
- Testing
- Valganciclovir
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
EBV Viremia, CMV Viremia
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the…
- Trial name
- NCT01329185
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
Transplant Recipients With CMV Infection
A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Resistance to antivirals is a growing problem in transplantation.that may concerns up to 5% of patients treated for cytomegalovirus (CMV) syndrome or disease in recent per-protocol studies.
- Trial name
- ORPHAVIC (NCT02067169)
- Testing
- CMV Infection
- Where
- 38 sites in France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Limoges
CMV
Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant
The ability to distinguish allogeneic hematopoietic cell transplantation (allo-HCT) recipients at risk for cytomegalovirus (CMV) reactivation from those who are not is central for optimal CMV management strategies.
- Trial name
- NCT03570411
- Testing
- T-SPOT®.CMV Test
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
CMV Viremia, CMV Disease
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
This is an expanded access protocol designed to provide access of ATA230 to subjects with cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no comparable treatment…
- Trial name
- NCT03010332
- Testing
- Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
- Sponsor
- Atara Biotherapeutics
CMV
Detection of Cytomegalovirus Virus in Neonates
To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
- Trial name
- CMV (NCT03251261)
- Testing
- illumigene CMV assay, illumipro-10
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 1,615 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
CMV Infections
Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- NCT02313857
- Testing
- Viralym-C
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- AlloVir
ANCA Associated Vasculitis, CMV Infection
CMV Modulation of the Immune System in ANCA-associated Vasculitis
The purpose of this study is to determine whether Cytomegalovirus (CMV) reactivation in ANCA-associated vasculitis (AAV) patients can be effectively and safely reduced using an antiviral agent (valaciclovir) and whether this in…
- Trial name
- CANVAS (NCT01633476)
- Testing
- Valaciclovir
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Professor Lorraine Harper
CMV Infection, EBV
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
To assess the safety and biological efficacy of therapeutically administered most closely HLA-matched third party donor-derived specific cytotoxic T lymphocytes (CTLs) targeting cytomegalovirus (CMV) or Adenovirus (Adv) or…
- Conditions
- CMV Infection, EBV, Adenovirus
- Trial name
- R3ACT (NCT02779439)
- Testing
- Virus specific CTLs
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Sydney
Cytomegalovirus, Kidney Transplantation
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
This study aims to validate whether Lophius Biosciences Kit T-Track® CMV is suitable to assess the functionality of CMV-specific cell-mediated immunity (CMI) and to determine a protective cut-off value for CMV…
- Conditions
- Cytomegalovirus, Kidney Transplantation, CMV Specific Immune Response
- Trial name
- CMValue (NCT02083042)
- Where
- Germany
- Volunteers
- 97 people
- Sponsor
- Lophius Biosciences GmbH
EBV Infection, CMV Infection
Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
Subjects have a type of blood cell cancer, other blood disease or a genetic disease for which they received a stem cell transplant.
- Conditions
- EBV Infection, CMV Infection, Adenoviral Infection
- Trial name
- EAP CHALLAH (NCT01945619)
- Testing
- Trivirus-Specific CTLs
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
HIV Infections, CMV Cytomegalovirus Retinitis
Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)
To test and evaluate the efficacy and safety of intravenous cidofovir (Vistide, previously known as HPMPC) for the treatment of retinitis.
- Trial name
- HPCRT (NCT00000142)
- Testing
- Cidofovir
- Volunteers
- 64 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Stem Cell Transplantation, Hematopoietic, CMV Infection
MSC for Treatment of CMV Infection
The purpose of this study is to evaluate the efficacy of mesenchymal stem cells (MSC) in the treatment of refractory cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Stem Cell Transplantation, Hematopoietic, CMV Infection, Hematological Diseases
- Trial name
- NCT02083731
- Testing
- MSCs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Nanfang Hospital, Southern Medical University
CMV Disease
Adoptive Immunotherapy for CMV Disease
Treatment strategy of patients: Stem cell engraftment (myeloablative or NST) for induction of host vs graft myeloablative transplantation tolerance.
- Trial name
- NCT00159055
- Testing
- CMV vaccine
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
CMV, Prenatal Diagnosis
Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?
Cytomegalovirus (CMV) is the largest member of the virus family Herpesviridae that infects almost all humans at some point in their lives (Ross, 2004).
- Conditions
- CMV, Prenatal Diagnosis, Ultrasound, MRI
- Trial name
- NCT00872703
- Where
- Israel
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wolfson Medical Center